Psoriatic Arthritis
News from the FDA/CDC
FDA approves adalimumab-bwwd biosimilar (Hadlima) in high-concentration form
The 100-mg/mL version of adalimumab-bwwd (Hadlima) is indicated for the same seven conditions as its 50-mg/mL counterpart.
From the Journals
Biosimilar-to-biosimilar switches deemed safe and effective, systematic review reveals
While switches between biosimilars of the same reference biologic already occur for biosimilars with indications in different specialties, they do...
Latest News
Study suggests psoriasis and PsA are underdiagnosed in underserved groups
“There needs to be improvement in access to quality dermatologic care, as this may help to reduce underdiagnosis of psoriasis and psoriatic...
News from the FDA/CDC
Ustekinumab becomes second biologic approved for PsA in kids
The approval is based on an extrapolation of data from adult trials in active psoriatic arthritis and adult and pediatric studies in moderate to...
Latest News
Topical roflumilast approved for psoriasis in adults and adolescents
In clinical trials, topical roflumilast was effective in treating psoriasis in intertriginous areas, including the buttocks, underarms, and...
Latest News
Questionnaire for patients with psoriasis might identify risk of axial involvement
A patient-completed questionnaire shows promise for detecting risk of undiagnosed axial involvement in psoriasis.
Latest News
NAFLD strongly correlated with psoriasis, PsA; risk linked to severity
The risk of nonalcoholic fatty liver disease is doubled by psoriasis, and severity is a related variable.
Feature
Methotrexate’s impact on COVID-19 vaccination: New insights made
New studies assess patients with various immune-mediated inflammatory diseases to determine the risks and benefits of pausing methotrexate after...
Conference Coverage
Neural networks can distinguish PsA from rheumatoid arthritis on MRI
Deep-learning programming can be trained to distinguish inflammatory joint diseases with reasonable accuracy.
Conference Coverage
New algorithm for initial PsA treatment choice is driven by
T-cell behavior
A novel treatment algorithm for psoriatic arthritis (PsA) is being developed to provide more precise biologic choices.
Latest News
Physicians urged to write indications on drug scripts as methotrexate users face new barriers with SCOTUS decision
Prior to the Supreme Court’s ruling, physicians were concerned about the impact an overturning of the 1973 law would have on patient access to MTX...